Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2013

Bayer Taps ChromoTek’s Drug Profiling Technology

  • Bayer Pharma has gained the right to use ChromoTek’s Cell Cycle Chromobody® technology for drug profiling by high-content analysis. Bayer will apply Chromobody technology for real-time monitoring of cell cycle progression in drug discovery.

    ChromoTek’s Chromobody technology is a universal live-cell imaging technology for high-content analysis. Chromobodies are single-domain antibodies that have been genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody technology allows users to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells.

    ChromoTek says that currently available Chromobodies trace cellular processes like cell cycle, apoptosis, DNA damage and repair, or allow cytoskeletal analysis. The Cell Cycle Chromobody cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a noninvasive manner while providing full flexibility to multiplex with other procedures, the firm reports.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »